| Popis: |
Rossi A, Butorac-Petanjek B, Chilosi M, Cosío BG, Flezar M, Koulouris N, Marin J, Miculinic N, Polese G, Samaržija M, Skrgat S, Vassilakopoulos T, Vukić-Dugac A, Zakynthinos S, Miravitlles M. Int J Chron Obstruct Pulmon Dis. 2017;12: 593–2610.Page 2604, Disclosure, the text “The authors report no conflicts of interest in this work” should read “BGC has received speaker fees from Chiesi, Novartis, Menarini, AstraZeneca, Esteve and Rovi; research grants from Chiesi and Boehringer; and served on advisory boards for Chiesi, Novartis, AstraZeneca and Esteve. MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL, Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharm, Verona Pharma, pH Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols. The authors report no other conflicts of interest in this work”.Read the original article |
